hbeag

RG7834 (RO 7020322) is a highly selective and orally bioavailable inhibitor of HBV, targeting HBsAg, HBeAg, and HBV DNA with IC50s of 2.8 nM, 2.6 nM, and 3.2 nM, respectively, in dHepaRG Cells.

Oleana-2,12-dien-28-oic acid is an HBsAg and HBeAg inhibitor that significantly inhibits HBV deoxyribonucleic acid (HBV-DNA) replication in HepG2.2.15 cells, making it relevant for the study of hepatitis B virus infection.

PROTACHBeAg degrader-1 is a PROTAC-based targeted degrader of HBeAg. It effectively recruits the VHL E3 ligase, yet its ability to degrade the hepatitis B virus protein (HBeAg) does not depend on VHL recruitment. This compound decreases levels of both secreted and intracellular HBeAg and is suitable for research involving the hepatitis B virus (HBV).

HBeAg ligand 1 (Compound S2) is an HBeAg inhibitor utilized in the synthesis of PROTAC HBeAg degrader-1.

ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).

BA-AZT1 acts as an inhibitor of HBV polymerase (HBV polymerase) and sodium taurocholate cotransporting polypeptide (NTCP). It hinders the secretion of viral capsid proteins HBsAg and HBeAg, with IC50 values of 0.65 µM and 13.42 µM, respectively, and inhibits HBV DNA replication with an IC50 of 0.70 µM.

ALG-001075, a capsid assembly modulator (CAM), is an orally active inhibitor of HBV. It effectively suppresses HBV DNA production in primary human hepatocytes and significantly reduces extracellular levels of HBsAg/HBeAg and intracellular HBV RNA. In AAV-HBV mouse models, ALG-001075 notably decreases HBV DNA levels. It can be utilized in research related to chronic hepatitis B (CHB).

Nirtetralin suppresses HBsAg and HBeAg expression.

HBV-IN-25 is a novel chemical compound that acts as a potent HBV cccDNA reducer when administered orally. It exhibits significant anti-HBeAg potency and anti-HBV activity, with IC50 values of 0.58 μM and 1.15 μM, respectively. Moreover, HBV-IN-25 demonstrates favorable aqueous solubility (LYSA＞452 μg/mL) and no cellular toxicity, making it a promising candidate for further investigation and development [1].

HBV-IN-24 (compound (2 S, 6S)-1a) is a potent inhibitor of HBV. HBV-IN-24 is a strong inhibitor of HBV DNA (EC50: 0.6 nM), HBsAg (EC50: 0.6 nM) and HBeAg (EC50: 4.6 nM). antiviral effect and was able to improve neurotoxicity.

Trans-ccc_R08 is a potent inhibitor of cccDNA (covalently closed circular DNA), displaying significant activity in decreasing HBeAg levels with an IC50 value of 0.08 µM. This compound shows promise for research into the treatment of Hepatitis B Virus (HBV) infection.

Libivirumab (17.1.41), a humanized monoclonal antibody targeting hepatitis B virus (HBV), demonstrates neutralizing activity with half maximal inhibitory concentrations (IC50) of 35 ng/mL for HBsAg and 130 ng/mL for HBeAg, respectively [1].

Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside (Compound 1), a lignan with anti-HBV activity, selectively targets the HBV surface antigen (HBsAg) with an IC50 of 0.58 mM, while its activity against the HBV e antigen (HBeAg) is significantly lower, with an IC50 of >2.4 mM. This compound can be isolated from the plant star anise [1].

Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside serves as an anti-hepatitis B virus (anti-HBV) agent, effectively inhibiting the secretion of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) in the Hep G2.2.15 cell line, with IC50 values of 1.67 mM for HBsAg and over 2.15 mM for HBeAg [1].

(+)-Sophoranol exhibits antiviral activity against the Coxsackie virus B3. It also shows potent anti-HBV activity with an inhibitory potency against HBsAg secretion and against HBeAg secretion.